Atherosclerosis Coronary heart disease
Conditions
Interventions
None listed
Sponsors
Amgen
Eligibility
Inclusion criteria
Inclusion criteria: 101. Subject has provided informed consent prior to initiation of any study specific activities/procedures. 102. Age 18 to 85 years. 103. History of ASCVD as demonstrated by either: a) MI (presumed type 1) And/or b) PCI (with high-risk features) with at least 1 of the following: - Age > 65 years -Diabetes mellitus - History of ischemic stroke - History of peripheral arterial disease - Residual stenosis >= 50% - Multivessel PCI (ie, >= 2 vessels, including branch arteries) See section 5.1 of the protocol.
Exclusion criteria
Exclusion criteria: 201. Subjects known to be currently receiving investigational drug in a clinical study that is anticipated to last > 1 year 202. Known Lp(a) value 10%) diabetes mellitus (type 1 or type 2). 205. Subject is receiving or has received lipoprotein apheresis to reduce Lp(a) within 3 months prior to enrollment. 206. Known uncontrolled or recurrent ventricular tachycardia in the past 3 months prior to enrollment. 207. Known malignancy (except non-melanoma skin cancers, cervical in situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years prior to enrollment. 208. Known history or evidence of clinically significant disease (eg, respiratory, gastrointestinal, or psychiatric disease) or unstable disorder or biomarker that, in the opinion of the investigator(s), would result in life expectancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Lp(a) value. -Lp(a) value >= 90 mg/dL or >=200 nmol/L for the subgroup of subjects with known Lp(a) value. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Lp(a) value. | — |
Countries
Netherlands
Outcome results
None listed